Member Info for Fadec92

Hi NiceNeil, high price options give me confidence and I think people need to be incentivised especially If your creating core values in a early business, then a share scheme is a more fair practice to share in the potential success in the future and will be better for us share holders!

But in phase 2 studies in combination with avelumab!

https://www.merckgroup.com/content/dam/web/corporate/non-images/business-specifics/healthcare/global/Healthcare-Pipeline.pdf

So this one didn’t synergies with chemo!

Merck’s ATR Inhibitor M6620 Formally (VX970)

“ATR inhibitor that showed promising preclinical activity. In spite of that early success, a study of 17 patients treated with the agent alone had only one response. It was very well tolerated as monotherapy, but significant toxicity emerged in a cohort that received VX-970 and carboplatin.”

So the long answer is that the mono-therapy trail has to take place to assess its toxicity and efficacy on its own with the data spread on the gene networks it works best with and it’s good enough and that it works!

It dose a specific job of Inhibiting CHk1 and it’s the best out there , the premise is that chemotherapy pushes the cancer into RS (Replication Stress) and looks for ways to repair itself and it’s pushed into the route of CHk1,Wee1 ATR to be able to repair the DNA strands so the more paths you Inhibit the more chance you have at killing cancer, but cancer has different genes/mutations and some Inhibiting paths work better for the type ie PARP Inhibitors break double strands (DSB) and work best in BRCA genes, so a combination is going to be much more effective, problem is with combinations is toxicity but it is thought that CHk1 is a good candidate to combo together with wee1, PARPS as the professionals at the top of the game have been vocal and said but needs clinic combo trails in next step!

To add (It synergies with gemcitabine and chemo can be more powerful with chk1 so you can reduce the amount of chemo which is brilliant in itself)

Stoney!

Rational Combination Approaches

Dr. Yap spoke about the use of combination strategies involving PARP inhibitors along with other agents. He pointed out that we may be coming full circle on this issue, as early efforts with PARP inhibitors involved combination approaches...

The main difficulty with combination therapy approaches is the development of overlapping toxicities, which can lead to subtherapeutic dosing. This was observed early on when both temozolomide and irinotecan were combined with several PARP inhibitors, and it continues to present a problem in developing new combination approaches.

“The question is, do we actually need rational combinations? My answer is yes,” Dr. Yap said. “Not all patients with BRCA1 and BRCA2 mutations will respond, and drug resistance is nearly inevitable.”

https://dailynews.ascopubs.org/do/10.1200/ADN.19.190298/full/

R. Plummer Is there too EORTC as mentioned she was the first to administer PARP at Newcastle, and Also as suggested the beyond PARP this publication is good to read, you have probably done so B4 with what Krone mentions with De Bono is fitting for chk1!

At EORTC

Plenary Session 3: Targeting DNA Repair, PARP, and Beyond

Publication:-

https://ascopubs.org/doi/pdfdirect/10.1200/EDBK_238473

RMM I can’t see it being presented any other way as it’s a poster presentation and the investor will need to have some skills to what is being said, I’ve said before investors are a lazy bunch, example

“IL-12 and IL-23 interleukin receptors, via activation of the transcription factors STAT4 and STAT3. IFNy production by T cells, mediated by IL-12 signalling, is highly dependent on TYK2”

The poster data as suggested by Tim in the peer review publication, with the group of investors here that pushed for data regarding some evidence with it rightly so though, but it was planned after all as said in the news issue!

“Plummer has also led studies bringing a new type of drug, called an ATR inhibitor, into the clinic through early-stage clinical trials. ATR, which stands for Ataxia telangiectasia and Rad3 related, regulates how cells respond to stress and can help promote DNA repair. Many cancer cells rely on ATR to survive.”

Also Ruth Plummer from Newcastle Northern ICR!

“Plummer wrote the first prescription in the world of a type of drug called a PARP inhibitor in 2003. Rucaparib was licenced to treat some women with advanced ovarian cancer in the EU in 2018 and the US in 2016. Plummer and the Newcastle team won a Translational Cancer Research Prize from Cancer Research UK for this work in 2010”

Yes and Udai Banerji!

https://www.aacr.org/Documents/1902079E_MolTar19_CFA_4_nc.pdf

Olaparib in men with advanced prostate cancer and gene defects!

“Treatment with olaparib resulted in a 66 per cent greater delay in disease progression”

https://www.icr.ac.uk/news-archive/esmo-2019-breast-and-ovarian-cancer-drug-outperforms-targeted-hormone-therapy-in-some-men-with-advanced-prostate-cancer?

Sierra has definitely got to pull their finger out, and get Chk1 moving, PARP Inhibitor and Chemotherapy!

Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer (SCLC)

https://cancerdiscovery.aacrjournals.org/content/early/2019/08/02/2159-8290.CD-19-0582

Queensland MOU Memorandum of understanding (Possible Licensing Deal)

• On 17 July 2019, QEM announced successful results using Petroteq Energy Inc’s technology, from Stage 2 test work carried out on the previous drill core sample.

• The test work undertaken by independent lab PRI Asphalt Technologies Inc, provided strong results, with total oil recovery up to 65% of the contained oil, from Julia Creek Project samples.

• With further optimisation by Petroteq, QEM is confident that recovery can be further increased.

• The residual material of approximately 20% of original mass (after oil recovery) was separated as a result of the Petroteq process, and this residual material contains the metals.

• The V205 is contained in the residual material only, as verified by PRI’s laboratory analysis.

• These results warrant a bulk sample test in order to produce sufficient oil and V205 required to carry out API (petrology analysis) testing of the oil, and V205 extraction.

• The bulk sample testing will provide a result that is a better representation for the beneficiation of the V205.

Queensland Vanadium Oil Sands Project Presentation August 2019

http://qldem.com.au/wp-content/uploads/2019/09/QEM_Investor_Presentation_August_2019.pdf

Other Links:-

http://qldem.com.au/project/

https://secureservercdn.net/50.62.89.138/gjz.e79.myftpupload.com/wp-content/uploads/2018/11/QEM_AX_IIR_181031.pdf

http://aigjournal.aig.org.au/julia-creek-vanadium-and-oil-shale-deposit/

Geology of Utah Tar Sands

https://geology.utah.gov/resources/energy/tar-sands/

Zacks Research Note:- https://scr.zacks.com

Original Version:-

https://s1.q4cdn.com/460208960/files/News/2019/Zacks_SCR_Research_06112019_PQEFF_Ralston.pdf

Short Version::-

https://wfn1.com/financial-news/columns/zacks-research/pqeff-zacks-initiates-coverage-of-petroteq-energy/

The interest is here already from large company’s which is validation in itself with a Non-Exclusive License Agreement in place with Valkor LLC for the CORT Technology/Process.

License Agreement:-

Under the Agreement, Valkor has agreed to pay Petroteq a non-refundable license fee of US$2 million per Plant in two payments, with 50% payable upon start of construction of a Plant and 50% payable upon first production of such Plant. Valkor also agreed to invest (or secure investment) of a minimum US$20 million towards the construction of a Plant by December 2020, and to have in production a minimum of 1,000 barrels per day. The agreement further provides that Valkor will pay Petroteq a five percent (5%) royalty based on annual gross sales, excluding solvent and or water, for so long as licensed technology is covered by a valid claim in the country in which it is used.

https://www.globenewswire.com/news-release/2019/07/02/1877278/0/en/Petroteq-Announces-Technology-Licensing-Agreement.html

Valkor Homepage:-

http://www.valkor-offshore.com

One of largest deposits of Oil Sands in the world :- 166 Billion Barrels!!

Buried in Alberta, Canada’s Oil Sands in Athabasca and at this field, the bitumen sits on top of a layer of limestone, which allows for surface mining!

The Technology used by the large companies is called SAGD system - (Steam Assisted Gravity Drainage)

The are concerns over its environmental impact are that the process involves high levels of water plus the operations produce large amount of greenhouse gasses because diesel engines are used to heat up the tanks to separate the oil so the process is not efficient!

The Technology used by the large companies work on SAGD system :- (Steam Assisted Gravity Drainage)

BP Oil Sands briefing:-

https://www.bp.com/content/dam/bp/business-sites/en/global/corporate/pdfs/sustainability/issue-briefings/bp-oil-sands-issue-briefing-2016.pdf

Too note they are looking for a new technology for their acreage positions, BP mentions:-

“Some of our oil sands opportunities remain under evaluation while we continue to monitor and assess emerging technologies and economic conditions to inform the best manner and timing of development”

The measurement for energy technology on how efficient is abbreviated to EROEI :- (Energy Returned Over Energy Invested)

A third party consultant, Chapman Petroleum Engineering performed an extensive energy analysis of MCW’s PetroTeq technology and the result was determined that the combined effect off all the Energy Saving features:-

The figure for SAGD is 4:1 EROEI Ratio!
CORT Technology is a 45:1 EROEI Ratio!

But to be Conservative it was Reduced to 22:1 to Account for Unforeseen Energy Losses!

PetroTeq is the first in Utah and USA to commercially produce surface oil sands based in Vernal, they recently completed re-engineering modifications/commissioning of the new equipment to the process/plant and have just started producing, the aim is to get somewhere between 1000 barrels continuous production per day which they will achieve in stepped process week by week!

The Projects:-

Asphalt Ridge facility in Vernal is a 1.5 Billion Barrels Deposit, the leases cover 2,542 gross acres of contingent resource of which 87.5 Million Barrels is recoverable on the leases.

Evaluation of Contingent Resource CPR by Chapman Petroleum Engineering:-

https://content.equisolve.net/_2f890012ef4beeb5d21edba60e3003cc/petroteq/db/207/2256/pdf/Report+OSB.pdf

Also

P.R Springs Project has recently been acquired and is a 4.5 Billion Barrels in place resource and own 8,480 gross acres of oil sands under U.S. federal oil ?and gas leases.

Latest Presentation:-

https://content.equisolve.net/petroteq/media/a9bc1245c1b816150e14fa309f4aa53c.pdf

Why PetroTeq stands out from other oil and gas producers.

https://mkt-petroteq.conversionir.com/asset/1:petroteq-report

PetroTeq patented technology is abbreviated to CORT (Clean Oil Recovery Technology)

It is environmentally friendly and the process produces zero greenhouse gas, zero waste and ?requires no high temperatures, it extracts 99% of the oil from oil sands and returns nearly clean sand back to the environment with a solvent based extraction that can be reused at a percentage of 99% recovery.

Here’s the Patent:-

Dr. Vladimir Podlipskiy

Patent no 9/884997

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=Podlipskiy-Vladimir-$.INNM.&OS=In/Podlipskiy-Vladimir-$&RS=IN/Podlipskiy-Vladimir-$

This Poster was in IOCS San Diego June 2017, over 2 years ago!

http://www.internationalcancercluster.org/uploads/9/8/5/8/98582788/sareum_iccs2017.pdf

RMM sorry about your friends!

If you can remember in an RNS it was said that SAR20351 could also be a backup molecule in case SDC-1801 was not good so they are closely related which you would think brings a similar production process I’m guessing!

“The company is also completing its assessment of further dual TYK2/JAK1 inhibitors for the potential treatment of certain cancers and/or as a back-up to SDC-1801 and expects to nominate this candidate in the near future.”

He done that on purpose Krone, he read your post! Lol..

RMM they could formulate the compound as they have orally dosed already!

“20351/SDC-1802 was dosed orally, as a monotherapy, or in combination with chemotherapy“

So this is for large production of compound!

“In addition, the Company has been exploring robust manufacturing routes to produce each candidate for preclinical and clinical studies. Such a route has been developed for SDC-1801 and activities continue to confirm a route of synthesis for SDC-1802.“

Additionally, we are seeing technological advances in the space that look set to reduce this cost per barrel even further, as well as alleviate some of the environmental impact of oil sands processing – something that falls in line with the Paris summit agreement.

Take MCW Energy Group Limited (TO:MCW), for example. The company, run by the former Exxon (N:XOM) president of Arabian Gulf operations, has developed a technology that allows for the processing of oil sands without any water (removing the possibility of water source pollution) and which uses a solvent to separate the bitumen instead of heat (which vastly reduces greenhouse gas emission.) Because a solvent is used, the byproduct of the process is clean sand, meaning it automatically meets the ELC criteria. Further, a report conducted in 2012 suggests the technology can produce at a cost of $24 a barrel.

So what’s the takeaway here? Well, oil sands will remain controversial, there’s no question about that. However, with the latest Paris summit targeting a 2-degree cap in global temperatures, the space has an opportunity to reform its image. With technology in the sector improving the environmental impact that oil sand production has in its mining regions, and the increasingly attractive per barrel economics, oil sand is here to stay – and at a time when the entire energy sector is under real pressure from markets, there may be opportunity in some of oil sand’s constituent companies to pick up an exposure at a discount.